Methazolamide-loaded solid lipid nanoparticles modified with low-molecular weight chitosan for the treatment of glaucoma: vitro and vivo study

References

• Edelhauser HF, Maren TH. Permeability of human cornea and sclera to sulfonamide carbonic anhydrase inhibitors. Arch Ophthalmol 1988;106:1110–15
   PubMed Web of Science ®Google Scholar
• Maren TH, Haywood JR, Chapman SK, Zimmerman TJ. The pharmacology of methazolamide in relation to the treatment of glaucoma. Invest Ophthalmol Vis Sci 1977;16:730–42
   PubMed Web of Science ®Google Scholar
• Epstein DL, Grant WM. Carbonic anhydrase inhibitor side effects. Serum chemical analysis. Arch Ophthalmol-Chic 1977;95:1378–82
   PubMed Web of Science ®Google Scholar
• Everitt DE, Avorn J. Systemic effects of medications used to treat glaucoma. Ann Intern Med 1990;112:120–5
   PubMed Web of Science ®Google Scholar
• Jiang S, Wang F, Zhu S, et al. Preformulation study of Methazolamide for topical ophthalmic delivery: physicochemical properties and degradation kinetics in aqueous solutions. Int J Pharm 2013;448:390–3
   PubMedGoogle Scholar
• Pepić I, Hafner A, Lovrić J, et al. A nonionic surfactant/chitosan micelle system in an innovative eye drop formulation. J Pharm Sci 2010;99:4317–25
   PubMed Web of Science ®Google Scholar
• Chen R, Qian Y, Li R, et al. Methazolamide calcium phosphate nanoparticles in an ocular delivery system. Yakugaku Zasshi 2010;130:419–24
   PubMed Web of Science ®Google Scholar
• Li R, Jiang S, Liu D, et al. A potential new therapeutic system for glaucoma: solid lipid nanoparticles containing methazolamide. J Microencapsul 2011;28:134–41
   PubMed Web of Science ®Google Scholar
• Qian Y, Wang F, Li R, et al. Preparation and evaluation of in situ gelling ophthalmic drug delivery system for methazolamide. Drug Dev Ind Pharm 2010;36:1340–7
   PubMed Web of Science ®Google Scholar
• Youshia J, Kamel AO, El SA, Mansour S. Design of cationic nanostructured heterolipid matrices for ocular delivery of methazolamide. Int J Nanomedicine 2012;7:2483–96
   PubMed Web of Science ®Google Scholar
• Mohd AK, Yasmin S, Asgar A, et al. Preparation, characterization, and evaluation of gatifloxacin loaded solid lipid nanoparticles as colloidal ocular drug delivery system. J Drug Target 2010;18:191–204
   PubMed Web of Science ®Google Scholar
• Iqbal MA, Md S, Sahni JK, et al. Nanostructured lipid carriers system: recent advances in drug delivery. J Drug Target 2012;20:813–30
   PubMed Web of Science ®Google Scholar
• Lian J, Zhang S, Wang J, et al. Novel galactosylated SLN for hepatocyte-selective targeting of floxuridinyl diacetate. J Drug Target 2008;16:250–6
   PubMed Web of Science ®Google Scholar
• Souto EB, Muller RH. Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes. Handb Exp Pharmacol 2010;197:115–41
   PubMedGoogle Scholar
• Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Delibery Rev 2007;59:478–90
   PubMed Web of Science ®Google Scholar
• Attama AA, Reichl S, Müller-Goymann CC. Diclofenac sodium delivery to the eye: in vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. Int J Pharm 2008;355:307–13
   PubMed Web of Science ®Google Scholar
• Hao J, Fang X, Zhou Y, et al. Development and optimization of solid lipid nanoparticle formulation for ophthalmic delivery of chloramphenicol using a Box-Behnken design. Int J Nanomed 2011;6:683–92
   PubMed Web of Science ®Google Scholar
• Müller-Goymann CC. Physicochemical characterization of colloidal drug delivery systems such as reverse micelles, vesicles, liquid crystals and nanoparticles for topical administration. Eur J Pharm Biopharm 2004;58:343–56
   PubMed Web of Science ®Google Scholar
• Garcia-Fuentes M, Prego C, Torres D, Alonso MJ. A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as carriers for oral calcitonin delivery. Eur J Pharm Sci 2005a;25:133–43
   PubMed Web of Science ®Google Scholar
• Luo Q, Zhao J, Zhang X, Pan W. Nanostructured lipid carrier (NLC) coated with chitosan oligosaccharides and its potential use in ocular drug delivery system. Int J Pharm 2011;403:185–91
   PubMed Web of Science ®Google Scholar
• Pandit AA, Dash AK. Surface-modified solid lipid nanoparticulate formulation for ifosfamide: development and characterization. Nanomedicine 2011;6:1397–412
   PubMedGoogle Scholar
• Kean T, Thanou M. Biodegradation, biodistribution and toxicity of chitosan. Adv Drug Deliv Rev 2010;62:3–11
   Google Scholar
• Patil S, Babbar A, Mathur R, et al. Mucoadhesive chitosan microspheres of carvedilol for nasal administration. J Drug Target 2010;18:321–31
   PubMed Web of Science ®Google Scholar
• Nagarwal RC, Kant S, Singh PN, et al. Polymeric nanoparticulate system: a potential approach for ocular drug delivery. J Control Release 2009;136:2–13
   Google Scholar
• Ana G. Chitosan nanoparticles: a survey of preparation methods. J Drug Target 2012;20:291–300
   PubMed Web of Science ®Google Scholar
• du Toit LC, Pillay V, Choonara YE, et al. Ocular drug delivery – a look towards nanobioadhesives. Expert Opin Drug Deliv 2011;8:71–94
   PubMed Web of Science ®Google Scholar
• Gan L, Wang J, Jiang M, et al. Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers. Drug Discov Today 2013;18:290–7
   PubMed Web of Science ®Google Scholar
• Mao S, Shuai X, Florian U, et al. The depolymerization of chitosan: effects on physicochemical and biological properties. Int J Pharmaceut 2004;281:45–54
   PubMed Web of Science ®Google Scholar
• Huang Q, Wang S, Huang J, et al. Study on the heterogeneous degradation of chitosan with hydrogen peroxide under the catalysis of phosphotungstic acid. Carbohydr Polym 2004;68:761–5
   Google Scholar
• Tian F, Liu Y, Hu K, Zhao B. Study of the depolymerization behavior of chitosan by hydrogen peroxide. Carbohyd Polym 2004;57:31–7
   Web of Science ®Google Scholar
• Kaur IP, Singh M, Kanwar M. Formulation and evaluation of ophthalmic preparations of acetazolamide. Int J Pharm 2000;199:119–27
   PubMed Web of Science ®Google Scholar
• Hämäläinen KM, Kananen K, Auriola S, et al. Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera. Invest Ophthalmol Vis Sci 1997;38:627–34
   PubMed Web of Science ®Google Scholar
• Monti D, Chetoni P, Burgalassi S, et al. Increased corneal hydration induced by potential ocular penetration enhancers: assessment by differential scanning calorimetry (DSC) and by desiccation. Int J Pharm 2002;232:139–47
   PubMed Web of Science ®Google Scholar
• O’Brien WJ, Edelhouse HF. The corneal penetration of trifluorothymidine, adenine arabinoside, and idoxuridine: a comparative study. Investig Ophthalmol Vis Sci 1977;16:1093–103
   PubMed Web of Science ®Google Scholar
• Ke TL, Graff G, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation 2000;24:371–84
   PubMed Web of Science ®Google Scholar
• Zambito Y, Colo GD. Thiolated quaternary ammonium–chitosan conjugates for enhanced precorneal retention, transcorneal permeation and intraocular absorption of dexamethasone. Eur J Pharm Biopharm 2010;75:194–9
   PubMed Web of Science ®Google Scholar
• Kassem MA, Abdel Rahman AA, Ghorab MM, et al. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm 2007;340:126–33
   PubMed Web of Science ®Google Scholar
• Zhou W, Wang Y, Jian J, Song S. Self-aggregated nanoparticles based on amphiphilic poly (lactic acid)-grafted-chitosan copolymer for ocular delivery of amphotericin B. Int J Nanomed 2013;8:3715–28
   PubMed Web of Science ®Google Scholar
• Kang B, Dai Y, Zhang H, Chen D. Synergetic degradation of chitosan with gamma radiation and hydrogen peroxide. Polym Degrad Stabil 2007;92:359–62
   Web of Science ®Google Scholar
• Mahmoud AA, El-Feky GS, Kamel R, Awad GE. Chitosan/sulfobutylether-β-cyclodextrin nanoparticles as a potential approach for ocular drug delivery. Int J Pharm 2011;413:229–36
   PubMed Web of Science ®Google Scholar
• Tian F, Liu Y, Hu K, Zhao B. The depolymerization mechanism of chitosan by hydrogen peroxide. J Mater Sci 2003;38:4709–12
   Google Scholar
• Motwani SK, Chopra S, Talegaonkar S, et al. Chitosan–sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and in vitro characterization. Eur J Pharm Biopharm 2008;68:513–25
   PubMed Web of Science ®Google Scholar
• Wu Y, Yao J, Zhou J, Dahmani FZ. Enhanced and sustained topical ocular delivery of cyclosporine A in thermosensitive hyaluronic acid-based in situ forming microgels. Int J Nanomed 2013;8:3587–601
   PubMed Web of Science ®Google Scholar
• Hong KN, Na YP, Shin HL, Samuel PM. Antibacterial activity of chitosans and chitosan oligomers with different molecular weights. Int J Food Microbiol 2002;74:65–72
   PubMed Web of Science ®Google Scholar
• Gratieri T, Gelfuso GM, Rocha EM, et al. A poloxamer/chitosan in situ forming gel with prolonged retention time for ocular delivery. Eur J Pharm Biopharm 2010;75:186–93
   PubMed Web of Science ®Google Scholar
• Sandri G, Bonferoni MC, Gökçe EH, et al. Chitosan-associated SLN: in vitro and ex vivo characterization of cyclosporine A loaded ophthalmic systems. J Microencapsul 2010;27:735–46
   PubMed Web of Science ®Google Scholar
• Garcia-Fuentes M, Torres D, Jośe Alonso M. New surface-modified lipid nanoparticles as delivery vehicles for salmon calcitonin. Int J Pharmaceut 2005;296:122–32
   PubMed Web of Science ®Google Scholar
• Davson H. The hydration of the cornea. Biochem J 1955;59:24–8
   PubMed Web of Science ®Google Scholar
• Zambito Y, Di Colo G. Thiolated quaternary ammonium–chitosan conjugates for enhanced precorneal retention, transcorneal permeation and intraocular absorption of dexamethasone. Eur J Pharmaceut Biopharmaceut 2010;75:194–9
   PubMed Web of Science ®Google Scholar
• Liu R, Liu Z, Zhang C, Zhang B. Gelucire44/14 as a novel absorption enhancer for drugs with different hydrophilicities: in vitro and in vivo improvement on transcorneal permeation. J Pharm Sci 2011;100:3186–95
   PubMed Web of Science ®Google Scholar
• Diebold Y, Jarrin M, Saez V, et al. Ocular drug delivery by liposome–chitosan nanoparticle complexes (LCS-NP). Biomaterials 2007;28:1553–64
   PubMed Web of Science ®Google Scholar
• Venkatesh S, Sizemore SP, Byrne ME. Biomimetic hydrogels for enhanced loading and extended release of ocular therapeutics. Biomaterials 2007;28:717–24
   PubMed Web of Science ®Google Scholar
• Gökçe EH, Sandri G, Egrilmez S, et al. Cyclosporine A-loaded solid lipid nanoparticles: ocular tolerance and in vivo drug release in rabbit eyes. Curr Eye Res 2009;34:996–1003
   PubMed Web of Science ®Google Scholar